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THE PATENTABILITY OF GENE EDITING TECHNOLOGIES
SUCH AS CRISPR & THE HARMONIZATION OF LAWS
RELATING TO GERMLINE EDITING
Jessica Wachowicz*
ABSTRACT
The following paper will discuss CRISPR, a process that allows for efficient gene
editing, and how it may be treated by various countries in light of the Trade Related
Aspects of Intellectual Property (TRIPS) Agreement and the Ordre Public doctrine.
This paper will focus specifically on how lawmakers and patent offices around the
world may address issues concerning the use of CRISPR for germline editing and how
countries can promote uniformity while maintaining their interest in protecting the
welfare of their citizens.
* Jessica Wachowicz (wachoj @uw.edu) is a third-year student at the University of Washington
School of Law whose primary area of study is emerging technologies and the legal issues
associated therewith.
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INTRODUCTION
Clustered Regularly Interspaced Short Palindromic Repeats ("CRISPR")
allows for the manipulation of human, plant, and animal DNA and has been
praised for its potential to treat cancer, remove inheritable diseases, and improve
agricultural production. CRISPR has also been criticized, as it can be applied in
the germline editing process, which may lead to "designer babies" - or parents
hand-selecting their child's physical or intellectual traits. Countries will have to
delineate between permissible uses of CRISPR and uses that are considered
immoral in their communities. Although The Agreement on Trade-Related
Aspects of Intellectual Property Rights ("TRIPS Agreement") sets minimum
standards that promote uniformity among international patent systems, an
exception exists in which a country may refuse to grant a patent for an invention
that is immoral or violates public order. This exception is known as the Ordre
Public doctrine or the Public Order doctrine, and whether a particular invention
falls within this exception will vary from one country to the next. Sections I and II
of this paper will provide an introduction to patent law, the TRIPS Agreement,
and the Paris Convention for the Protection of Industrial Property ("Paris
Convention"). Sections III and IV will describe the CRISPR process and how it
may be used in coming years. Section V will discuss the public order doctrine in
greater detail and identify the ways in which TRIPS member nations have used it
in the past, and Section VI will analyze the future of CRISPR in the international
patent system and a potential solution for harmonizing laws pertaining to germline
editing with CRISPR.
I. THE EMERGENCE OF THE PATENT SYSTEM
Patent law is a bargained exchange in which an inventor discloses to the public
how an invention can be created in exchange for monopoly power over the
product or invention for a specified period of time. Although allowing individuals
or entities to obtain monopoly power is generally discouraged, an exception is
made in the patent law system for new inventions. The policy justification behind
such a system is that it encourages individuals and entities to invest in the creation
of new products, which often requires significant research and development costs,
time, and resources. This patent grant allows inventors to price the product in a
way that will allow them to recover such costs. When the term of the patent
expires, others in the community are free to produce the same product and sell it
at a lower price point.
Patent law's roots can be traced back to 500 BCE, where chefs in an ancient
Greek city were able to obtain a one-year monopoly on culinary dishes they
created.' Beginning in the 1400s, patents began to be granted for technological
1 University of Southern California School of Law, History of Patent Law, USC GOULD ONLINE
BLOG, https://onlinellm.usc.edu/resources/infographics/history-of-patent-law/.
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inventions, architecture, stained glass, and more. 2 The patent system as it exists
today is heavily influenced by the Statute of Monopolies passed in 1623 by the
English Parliament. 3 The founders of the United States believed the Statute of
Monopolies to be successful in promoting innovation, and thus the United States
Constitution granted Congress the authority to protect rights of inventors.4 Only a
handful of countries are without a patent system today, including South Sudan,
Somalia, Afghanistan, and Myanmar. 5
II. TREATIES GOVERNING PATENTS
The TRIPS Agreement, administered by the World Trade Organization, is one
of the most impactful treaties governing intellectual property and has been signed
by 164 countries.6 The purpose of this agreement was to promote uniformity by
creating minimum standards for the protection and enforcement of intellectual
property rights, including patent rights. 7 As innovation began to spur during the
Industrial Revolution and as goods began to cross borders with greater ease,
inventors sought to have their creations protected in multiple countries. Thus, a
convention was held to create international standards for patents. 9 The first
international agreement established relating to intellectual property was the Paris
Convention, which was signed in 1883 and still has great force in the intellectual
property world today. 10 Article 2 of TRIPS states that members shall comply with
numerous provisions set forth in the Paris Convention.11
The Paris Convention set forth numerous minimum standards, but it did not
impose standards relating to the subject matter of patents.12 This was troublesome,
as many countries disagreed as to what constituted patentable subject matter. 13
For example, biotechnology and pharmaceuticals were not considered patentable
by many countries, particularly developing countries, because they did not support
the notion of increasing the cost of medicine or healthcare.14 Inconsistencies
among countries lead to the Uruguay Round, negotiations to amend the Paris
2 id.
3 id.
4 id.
Louis Hoffman, Countries in which the Patent Cooperation Treaty (PCT) Does Not Apply,
HOFFMAN PATENT FIRM (Feb. 24, 2015), www.valuablepatents.com/non-pct-countries/.
6 See Daniel C.K. Chow & Edward Lee, International Intellectual Property Problems, Cases, and
Materials 1, 17-18 (3rd ed. 2017).
7 See Carlos Correa, Trade Related Aspects of Intellectual Property Rights: A Commentary on the
TRIPS Agreement (Oxford University Press, 2007).
8 See Chow & Lee, supra note 6, at 293.
9Id.
'o See id.
"Id. (citing TRIPS Article 2).
12 See Daniel C.K. Chow & Edward Lee, International Intellectual Property Problems, Cases, and
Materials 1, 294 (3rd ed. 2017).
13 Id.
14 Id.
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Convention . These negotiations resulted in minimum standards set forth in the
TRIPS Agreement that prohibited countries from denying patent protection based
on the field of technology.16 Thus, countries could no longer deny the
patentability of pharmaceuticals or biotechnologies. Although, there are some
permissible exceptions in which a patent may be denied based on its subject
matter. Patents can be denied for certain methods relating to medical treatment,
plants and animals (other than microorganisms), and inventions that are
considered "immoral" or violate "ordre public."
III. Clustered Regularly-Interspaced Short Palindromic Repeats
(CRISPR)
CRISPR, or clustered regularly-interspaced short palindromic repeats, allows
for the editing of DNA. 17 The technology has been likened to the "Find and
Replace" function of a word processor, as CRISPR technology can identify
problematic or disease-causing portions of an individual's genetic code and
replace or repair them. Although gene editing is not a new concept, CRISPR
provides a more efficient, accurate, and cost-effective solution.19 Understanding
the function of DNA and RNA are essential to the understanding of CRISPR
technologies. DNA, which stores genetic information, has the ability to control
cells through a protein synthesis process, otherwise known as gene expression. 20
Complementary RNA strands are created for the purpose of transferring genetic
code information from the nucleus to the ribosome in order to create proteins. 21
Thus, the DNA can transmit genetic information needed for protein creation while
remaining safely in the nucleus.22 CRISPR "was adapted from a naturally
occurring genome editing system in the bacteria ... [and in nature, such] bacteria
capture[s] snippets of DNA from invading viruses and use[s] them to create DNA
segments known as CRISPR arrays."23 The bacteria can remember certain viruses,
and, if identified in the future, can target the virus' DNA by producing RNA from
the CRISPR arrays.24 The bacteria uses an enzyme to cut the virus' DNA. 25
Researchers were able to modify RNA to include a guide sequence that targets
1 Id. at 295.
16 id.
17 Robin Feldman, The CRISPR Revolution: What Editing Human DNA Reveals About the Patent
System's DNA, 64 UCLA L. REV. 392, 392 (2016).
" Id. at 394.
19 Id.
20 Biology Primer: DNA and RNA, COMPUTATIONAL MEDICINE CENTER AT THE SIDNEY KIMMEL
MEDICAL COLLEGE OF THOMAS JEFFERSON UNIVERSITY, https://cm.jefferson.edu/learn/dna-and-
rna/.
21 Id.
22 Id.
23 What are genome editing and CRISPR-Cas9?, U.S. NATIONAL LIBRARY OF MEDICINE -
GENETICS HOME REFERENCE (May 19, 2018),
https://ghr.nlm.nih.gov/primer/genomicresearch/genomeediting.
24 Id.
25 Id.
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specific DNA sequences.26 The modified RNA attaches to the enzyme and can
locate and cut the DNA in the same manner as it occurs in nature.27 Researchers
then "use the cell's own DNA repair machinery to add or delete pieces of genetic
material, or to make changes to the DNA by replacing an existing segment with a
customized DNA sequence."28
IV. POTENTIAL CRISPR APPLICATIONS
A. Curing Disease
As stated previously, CRISPR technology has the ability to edit plant, animal,
and human genes.29 The most promising CRISPR application in humans is the
editing of genes in a way that fights disease. 30 Researchers have conducted studies
on mice and have corrected mutations that "cause sickle-cell anemia, muscular
dystrophy, and cystic fibrosis."31 Clinical trials will soon be conducted for a
technique that uses CRISPR technology to cure a rare form of blindness. 32
Further, CRISPR presents possibilities to edit away inheritable diseases and
congenital conditions.
B. Plant Life
CRISPR can also be applied to plants to accomplish industrial tasks. 33 For
example, Chinese scientists are using the technology to delete genes in wheat
strains in order to make the strains more resistant to certain pests. 34 In 2017,
Japanese researchers used CRISPR to change the color of a flower from violet to
white by editing a single gene.35
C. Drug Development
Drug developers are also excited about the possibilities presented by CRISPR
technology. Because CRISPR can modify hundreds of thousands of genes at one
26 Id.
27 Id.
28 What are genome editing and CRISPR-Cas9?, U.S. NATIONAL LIBRARY OF MEDICINE -
GENETICS HOME REFERENCE (May 19, 2018),
https://ghr.nlm.nih.gov/primer/genomicresearch/genomeediting.
29 Feldman, supra note 17, at 394.
30 Id.
31 Id. at 399.
32 Id.
33 Id. at 394.
34 Robin Feldman, The CRISPR Revolution: What Editing Human DNA Reveals About the Patent
System's DNA, 64 UCLA L. REV. 392, 399 (2016)..
35 See Laboratory Equipment, In world-first, Japanese scientists use CRISPR to change flower
color, GENETIC LITERACY PROJECT (Sept. 8, 2017),
https://geneticliteracyproject.org/2017/09/08/world-first-japanese-scientists-crispr-change-flower-
color/.
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time, researchers can test for possible causes of illness with greater ease.36 For
example, "[c]ancer cells often need to be targeted by multiple drugs, and their
susceptibility may vary from patient to patient. CRISPR will permit more rapid,
systematic testing and modeling of how cancers develop and how they can be
defeated."37
D. Transplantation
CRISPR technology may also be used to improve the organ transplantation
process.38 The transplantation of organs from pigs to humans has long been a
concept in the medical community, but problems often arise due to certain types
of bacteria found in pig DNA. 39 CRISPR technology can potentially be used to
edit the harmful bacteria out of the pig DNA so as to increase the likelihood of
success in the transplantation process..40
E. Germline Cell Editing
Although the discourse regarding CRISPR has been largely positive due to the
potential problems it may solve, there are many who are concerned about its
potential uses. Thus far, CRISPR editing techniques are "limited to somatic cells,
which are cells other than egg and sperm cells. These changes affect only certain
tissues and are not passed on from one generation to the next."41Altering egg
cells, sperm cells, or genes in an embryo can result in such changes being passed
down through generations and is known as germline editing or genome editing. 42
Germline and genome editing have been controversial for many years, as concerns
have been expressed over "eugenics and 'designer babies' created to maximize
intelligence and attractiveness." 43 Although germline and genome cell editing
techniques are illegal in many countries, China has evidenced a willingness to
experiment in this area. In 2015, Chinese scientists attempted to use CRISPR
technology to repair a gene for a blood disorder in non-viable embryos. 44 This
year, a Chinese scientist announced that he used CRISPR to alter genes in
embryos that would make the babies resistant to H.I.V. 45 The embryos were later
36 Feldman, supra note 17, at 399.
37 Id.
38 Id.
39 Id.
40 Id.
41 See What are genome editing and CRISPR-Cas9?, U.S. NATIONAL LIBRARY OF MEDICINE -
GENETICS HOME REFERENCE (May 19, 2018),
https://ghr.nlm.nih.gov/primer/genomicresearch/genomeediting.
42 Id.
43 Feldman, supra note 17, at 400.
44 Id.
45 See Gina Kolata, Sui-Lee Wee and Pam Belluck, Chinese Scientist Claims to Use Crispr to
Make First Genetically Edited Babies, NEW YORK TIMES (Nov. 26, 2018),
htt i' W Kf fms~cm/2O8/11/26heath!ene~ditn~ies-china~htm1.
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implanted in the mother's womb and resulted in the birth of two twin girls. 46
Although, this scientist, who operated in secret and published his findings via
social media, received significant backlash from the scientific communities in
China and around the world.4 7 The United States currently has a ban on germline
editing and has stated that there should be a "broad societal consensus" on clinical
uses of germline editing before the ban is lifted.4 8
V. ORDRE PUBLIC DOCTRINE
The concept of moral utility emerged in England, as the Statute of Monopolies
banned patents on inventions that were contrary to public policy. 49 In 1883, some
participants of the Paris Convention believed that patents should not "mislead the
public," and thus a compromise was made and the "ordre public" exception was
incorporated.5 0 The ordre public exception was later incorporated into the TRIPS
agreement in 1994 and was signed by the 182 countries that comprised the World
Trade Organization. 5 1
Article 27.2 of the TRIPS Agreement states that "[m]embers may exclude from
patentability inventions, the prevention within their territory of the commercial
exploitation of which is necessary to protect ordre public or morality, including to
protect human, animal or plant life or health or to avoid serious prejudice to the
environment, provided that such exclusion is not made merely because the
exploitation is prohibited by their law." No guidance is included in TRIPS as to
what constitutes immorality, thus public order exclusions vary among countries.52
One interpretation states that an invention that falls within the ordre public
exception "expresses concerns about matters threatening the social structures
which tie a society together i.e. matters that threaten the structure of civil society
as such. Morality has been interpreted as the "degree of conformity of an idea
to moral principles."54 It is clear, based on differing cultures and societal norms,
that each country will have a separate concepts of what constitutes an immoral
invention. The following sections will discuss how the ordre public exception or
46 Id.
47 See Caroline Wagner, CRISPR babies and other ethical missteps in science threaten China's
global standing, THE CONVERSATION (Dec. 4, 2018), 1 r-babies-and-
other-ethical-isst08009 .
48 Id.
49 See Paul Spiel, Deceptive Patents: Deconstructing Juicy Whip, 2017 BYU L. REV. 743, 746
(2018).
50Id.
51 Id. at 747.
52 See Singh & Associates, Ordre public and morality exclusions from patentability, LEXOLOGY
(Sept. 29, 2012), https://www.lexology.com/library/detail.aspx?g=eleff8bb-ae9d-4b20-bc95-
68dd27f5aa07.
53 Id.
54 Id.
55Id.
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principles of morality have played a role in different countries' patent systems and
how, if at all, this doctrine has affected the use of CRISPR in germline editing.
A. United States
The Patent Act states that an invention must be "useful" in order to be eligible
for patentability.56 Justice Story, a leader in developing patent law in the United
States, stated in Lowell v. Lewis that inventions must meet a certain threshold of
moral utility. 57 Among the list of examples Justice Story gave, inventions that
would "promote debauchery" or were deceptive in nature did not pass muster
under the moral utility doctrine. Courts barred the patentability of a number of
inventions, such as gambling machines, over the following years pursuant to
Justice Story's holding. 59 The Supreme Court later determined that limiting the
scope of patentability should be left to Congress.60 The Court stated that
"'inventions directed to human/non-human chimera could, under certain
circumstances, not be patentable because, among other things, they would fail to
meet the public policy and morality aspects of the utility requirement."' 61
As stated previously, the United States currently bans germline editing and is
waiting for a global consensus on the issue before deciding whether to lift the ban.
The ban only applies where the edited embryo will be transplanted into a womb to
62be birthed. Recently, researchers were able to conduct a CRISPR study on
embryos that were developed for only a few days with no intention of
63transplantation into a womb. This study was met with criticism, with the U.S.
intelligence community deeming CRISPR a potential weapon of mass
destruction.64
B. Europe
The European Patent Convention and the Biotech Directive bars the
patentability of many potential uses of CRISPR. Article 53(a) of the European
Patent Convention states that no patent shall be granted if it is against public order
or morality, including "processes for modifying the germ line genetic identity of
human beings [and] uses of human embryos for industrial or commercial
purposes."65 Thus, under Article 53(a), the use of CRISPR on genomes would be
barred. The term "use" has been debated, as some have argued that the embryos
56 Spiel, supra note 49, at 747.
57 Id.
5 See id. at 748.
59 Id.
60 See Viola Prifti, The limits of "ordre public" and "morality" for the patentability of human
embryonic stem cell inventions, J. WORLD. INTELLECT. PROP. 1, 4 (2018) (citing Diamond v.
Chakrabarty, 447 U.S.303, 318 (1980)).
61 Id.
62 See Steve Connor, First Human Embryos Edited in U.S., MIT TECHNOLOGY REVIEW (July 26,
2017), https://www.technologyreview.com/s/608350/first-human-embryos-edited-in-us/.
63 Id.
64 Id.
65 Prifti, supra note 57, at 7.
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must be used in the inventive process to be barred, while others have argued that
66
any process that involves or destroys an embryo is banned. The EU Court of
Justice later clarified the clause, stating that so long as the use of the embryo is for
"therapeutic and diagnostic purposes" and the invention is useful to the embryo,
67 6the invention may be patentable. The term "useful" was not defined.6 8
"The European Court of Justice recently ruled that the use of CRISPR on crops
or in the drug development process need not be regulated as strictly as genetically
modified organisms (GMOs)", but the use of CRISPR on embryos has not been
discussed by the Court. 69
C. China
Under Article 5.1 of the CPL, it states that the patent office may not grant a
patent for an invention that is against "the laws or social morality or . . . is
detrimental to public interest." 70 There are no laws that prohibit CRISPR
technology, thus it must be determined whether the technology is detrimental to
public interest.7 1 A guideline used by the Chinese patent office in determining the
bounds of the morality considers "social morality to be ethical or moral norms and
rules generally recognized as justifiable and acceptable by the Chinese public." 72
The guidelines give examples of certain biotechnologies that would be barred
from patentability, such as editing the genes of animals in a way that causes
suffering without medical benefit to humans or animals, cloning humans, or using
human embryos for industrial or commercial purposes. 73 The guidelines state that
any process that modifies a human's genetic identity is barred from patentability,
but no law exists in china governing the use of CRISPR. 74 Chinese law
technically bans gene editing on human embryos, but most researchers have been
able to conduct experiments with CRISPR by using non-viable embryos or cloned
embryos.75
Many patent applications regarding the use of CRISPR have been submitted to
76
the Chinese State Intellectual Property Office thus far. As stated previously,
66 Id. at 7-8.
67 Id. at 8.
68 Id.
69 See Alex Dale, European Court Supports the softening of CRISPR Gene Editing Rules,
LABIOTECH.EU (Jan. 22, 2018), https://labiotech.eu/crispr-gene-editing-court/.
70 Ana Nordberg, Cutting edges and weaving threads in the gene editing revolution: reconciling
scientific progress with legal, ethical, and social concerns, 5 Journal of Law and the Biosciences
35 (2018) (citing Yaojin Peng, How morality and ethics governs the Chinese patent process, 34
NATURE BIOTECHNOLOGY 616, 616-618 (2016)).
71 Id.
72 Id.
73 Id.
74 Id.
75 See Skye Gould & Kevin Loria, This map shows were researchers might design the first
genetically engineered baby, BUSINESS INSIDER (Oct. 20, 2015), www.businessinsider.com/what-
countries-allow-researchers-to-edit-human-embryos-2015-10.
76 See Peng, supra note 67.
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China has been testing the use of CRISPR on non-viable embryos.77 Recently, a
group of researchers cloned embryos that contained a blood disorder.78 Using
CRISPR, the researchers were able to cut the problematic genes and replace them
with other genetic material.79 Chinese researchers are continuing to conduct these
studies, despite concerns over whether the technology will be patentable.80
VI. HARMONIZING THE TREATMENT OF GENE EDITING TECHNOLOGIES
At present, countries take different approaches in applying the ordre public
doctrine to cases involving germline editing. In Japan, the patent office examines
scientific guidelines pertaining to stem cell research in rendering its decisions.8 1
Others simply look to the values held by that particular country in determining
whether the invention would benefit society.82
Looking at the values held by a particular community will lead to varying
results. Some countries may value the welfare of individuals over the progression
of science.83 Others argue that because these inventions can dramatically improve
healthcare, and because healthcare is a human right, this public interest should
override any bans on germline editing. 84
A similar dispute arose under TRIPS with respect to pharmaceuticals. As stated
previously, some countries, India in particular, argued that patenting
pharmaceuticals was immoral because it raised the cost of healthcare. In 2016,
the World Health Organization published the "Guidelines for the examination of
patent applications relating to pharmaceuticals."86 The purpose of this guideline
was to assist legislators in crafting laws that would allow for the patentability of
pharmaceuticals generally, while imposing limitations that would prevent
healthcare from becoming unaffordable.
One plausible solution is for the World Health Organization to create a set of
guidelines for determining the patentability of technologies such as CRISPR. The
guideline can look to other international treaties that focus on the preservation of
human rights and the improvement of healthcare.87 By encouraging countries to
take these agreed upon policy objectives into consideration when examining these
controversial patents, results among different patent offices may be slightly less
varied. A guideline from the World Health Organization (WHO) or a similar
77 Feldman, supra note 17, at 400.
78 See David Cyranoski, Chinese scientists fix genetic disorder in cloned human embryos, NATURE
(Oct. 2, 2017), https://www.nature.com/news/chinese-scientists-fix-genetic-disorder-in-cloned-
human-embryos-1.22694.
79 Id.
80 Id.
" See Prifti, supra note 57, at 13.
82 Id. at 12.
83 Id. at 14.
84 Id.
5 See Jakob Wested & Timo Minssen, TRIPS and the Life Sciences - Perspectives on Limitations
to Patentability (Univ. of Copenhagen Faculty ofL. Research Paper No. 2017-37, 2017)
86 Id.
87 See Prifti, supra note 57, at 12.
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organization may assist countries' legislatures in crafting laws that allow for
progression in this field of science while protecting their communities from
potential human rights violations, such as the destruction of viable embryos.
Attempts at harmonization have been made in the past. There are currently
numerous international instruments that prohibit inventions involving genomes,
such as the UNESCO Universal Declaration on Bioethics and Human Rights and
the Oviedo Convention for the Protection of Human Rights and Dignity of the
Human Being with regard to the Application of Biotechnology and Medicine:
Convention on Human Rights and Biomedicine. The former states that public
welfare should be prioritized over the progress of science, and the latter states that
genetic modification techniques should only be allowed if "serious hereditary sex-
related disease[s] [are] to be avoided."89 These agreements make clear that public
welfare is of primary importance, and that germline editing techniques should
only be applied where serious risks can be avoided. The Oviedo Convention
limited the scope of the exception to the avoidance of sex-related diseases, but
perhaps with the introduction of CRISPR, countries may need to consider the
circumstances under which genome and germline editing may be permissible.
CONCLUSION
In summary, relying on the ordre public doctrine to determine the patentability
of CRISPR technology will lead to dramatically varying results around the world.
The need for a more harmonized approach is present. Despite countries' general
avoidance of genome and germline editing, technology has developed in such a
way that these practices may be highly beneficial to public welfare. Countries
should reconsider their stances on such practices in light of the potential benefits
CRISPR technology can offer and should attempt to reach a general consensus on
the proper uses of CRISPR. Given recent events, the WHO should promptly issue
guidelines to assist legislatures in crafting laws that promote progress in this area
while maintaining consistency with concepts of morality.
" Id. at 13.
89 Id.
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